Literature DB >> 10097222

Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction.

D Hasdai1, A Lerman, C S Rihal, D A Criger, K N Garratt, A Betriu, H D White, E J Topol, C B Granger, S G Ellis, R M Califf, D R Holmes.   

Abstract

BACKGROUND: Because of the increased propensity of intracoronary thrombi to form in cigarette smokers, percutaneous transluminal angioplasty (PTCA) for acute myocardial infarction (AMI) may be less effective in smokers. We sought to determine the impact of smoking status on outcome after PTCA for AMI.
METHODS: Patients enrolled in the GUSTO IIb Angioplasty Substudy were randomly assigned to receive PTCA or tissue-plasminogen activator (tPA) for AMI. The interaction of smoking status (nonsmokers = 344, former smokers = 294, current smokers = 490) and treatment strategy with the occurrence of death, nonfatal reinfarction, or nonfatal, disabling stroke at 30 days was analyzed. Procedural success (residual stenosis <50% and Thrombolysis in Myocardial Infarction [TIMI] flow grade 3) was also analyzed for patients who underwent PTCA (n = 444).
RESULTS: Among patients who underwent PTCA, nonsmokers had worse percent stenosis of the culprit lesion before reperfusion (P =.03) and more often had TIMI flow grade 0 (P <.05). Procedural success was more common in smokers (65.6%) than in former smokers (53.3%) and nonsmokers (52. 4%; P =.02), reflecting a higher rate of postprocedure TIMI 3 flow. PTCA was associated with a better 30-day outcome than tPA for current smokers (odds ratio [95% confidence interval] = 0.41 [0.19 to 0.88]), with a similar trend for former smokers (0.73 [0.34 to 1. 58]) and nonsmokers (0.77 [0.42 to 1.40]). At 6 months, smokers randomly assigned to PTCA also had fewer deaths and reinfarction (0. 58 [0.31 to 1.07]).
CONCLUSIONS: Although smoking status affects angiographic variables before and after PTCA for AMI, PTCA is associated with a better 30-day outcome than tPA regardless of smoking status and should be considered when readily available.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10097222     DOI: 10.1016/s0002-8703(99)70213-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  "Smoker's Paradox" in Patients Treated for Severe Injuries: Lower Risk of Mortality After Trauma Observed in Current Smokers.

Authors:  Teresa M Bell; Demetria R Bayt; Ben L Zarzaur
Journal:  Nicotine Tob Res       Date:  2015-02-02       Impact factor: 4.244

2.  Impact of smoking status on cardiovascular outcomes following percutaneous coronary intervention.

Authors:  Burhan Mohamedali; Adhir Shroff
Journal:  Clin Cardiol       Date:  2013-05-13       Impact factor: 2.882

3.  Cardiovascular risk factors and clinical presentation in acute coronary syndromes.

Authors:  A Rosengren; L Wallentin; M Simoons; A K Gitt; S Behar; A Battler; D Hasdai
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

4.  The smoker's paradox: insights from the angiographic substudies of the TIMI trials.

Authors:  Brad G Angeja; Sarah Kermgard; Michael S Chen; Matthew McKay; Sabina A Murphy; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

5.  The effects of facilitated primary PCI by guide wire on procedural and clinical outcomes in acute ST-segment elevation myocardial infarction.

Authors:  Volkhard Kurowski; Evangelos Giannitsis; Dirk P Killermann; Uwe K H Wiegand; Ralph Toelg; Hendrik Bonnemeier; Franz Hartmann; Hugo A Katus; Gert Richardt
Journal:  Clin Res Cardiol       Date:  2007-06-04       Impact factor: 5.460

6.  A history of smoking is associated with improved survival in patients treated with mild therapeutic hypothermia following cardiac arrest.

Authors:  Jeremy S Pollock; Ryan D Hollenbeck; Li Wang; David R Janz; Todd W Rice; John A McPherson
Journal:  Resuscitation       Date:  2013-09-12       Impact factor: 5.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.